U.S., April 10 -- ClinicalTrials.gov registry received information related to the study (NCT06920251) titled 'Phase II Trials of Letermovir Prophylaxis in Patients With RRMM Undergoing Elranatamab Therapy' on March 26.
Brief Summary: This is an open-label, single arm, multicenter study to evaluate the efficacy of letermovir in the prevention of clinically significant CMV infection in adult, CMV-seropositive relapsed/refractory MM patients undergoing BsAbs therapy.
Study Start Date: May 01
Study Type: INTERVENTIONAL
Condition:
Relapsed Refractory Multiple Myeloma (RRMM)
Intervention:
DRUG: Letermovir
Elranatamab: Participants will receive SC administration of elranatamab QW, Q2W or Q4W. The initial doses of elranatamab will be 12 mg ...